alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
EXECUTIVE OFFICE OF THE PRESIDENT

OFFICE OF THE UNITED STATES TRADE REPRESENTATIVE

WASHINGTON, D.C. 20508

January 4, 2019

RE: Product Exclusion Request Number: USTR-2018-0025-4738

Arrowhead Electrical Products, Inc:

The purpose of this letter is to inform you that the product exclusion request referenced 

above has been denied. As you are aware, USTR published a Federal Register notice (83 FR 

28710) on June 20, 2018, that announced the Trade Representative’s determination to impose an 

additional duty of 25 percent on certain products from China. On July 11, 2018, the Trade 

Representative published a Federal Register notice (83 FR 32181) which announced that a 

process had been established under which interested persons could request that products falling 

within a covered HTSUS subheading be excluded from the additional duties announced on June 

20. 

Your request was reviewed in accordance with the factors and procedures set forth in 

Section B(1) of the July 11 notice. Based on that review, and after careful consideration, your 

request was denied because the request failed to show that this particular product is available 

only from China.

Because USTR will grant exclusion requests on a product specific basis, you may still 

benefit from a product exclusion if a similar product is granted an exclusion. Products for which 

an exclusion has been granted will be periodically announced on the USTR website. Product 

exclusions will become legally effective once published in the Federal Register. 

Sincerely,

Stephen P. Vaughn
EXHIBIT
10.3


 


***Text Omitted and Filed Separately with the
Securities and Exchange


Commission. 
Confidential Treatment Requested Under


17 C.F.R.
Sections 200.80(b)(4) and 240.24b-2


 


[Amylin Letterhead]


 


February 11,
2010


 


Baxter
Pharmaceutical Solutions LLC


927
South Curry Pike


Bloomington,
Indiana 47403


Attn:  Brik Eyre


 


	
  Re:

  	
   

  	
  Commercial Supply Agreement
  between Baxter Pharmaceutical Solutions LLC (“Baxter”) and Amylin
  Pharmaceuticals, Inc. (“Amylin”) dated as of March 2, 2005 (the
  “Agreement”) for Symlin (“Product”)

  



 


Dear
Brik:


 


This
letter will confirm that Amylin and Baxter have agreed to amend the Agreement (i) to
delete in its entirety the Annual Obligation for Year Five (calendar year 2009)
such that Amylin shall have no further obligation to purchase from Baxter an
Annual Obligation for calendar year 2009 and (ii) to add a requirement for
Amylin to pay to Baxter a minimum of [***] in calendar year 2010, which
requirement may be satisfied by (a) the purchase by Amylin of Product
under the Agreement or (b) the purchase by Amylin of any other product or
service under another agreement, or (c) the payment to Baxter in [***] of
[***], provided, however, for (b) and (c) that if such other product
or service is subject to a minimum annual obligation for calendar year 2010 in
place as of the date of this letter agreement, then such payment shall satisfy
the requirement under this letter agreement only to the extent such payment
exceeds the minimum annual obligation for [***].


 


Unless
otherwise stated in this letter agreement, each capitalized term shall have the
same meaning ascribed to it in the Agreement. 
This letter contains the entire understanding and agreement between
Baxter and Amylin and supersedes all prior agreements and understandings
relating to the subject matter hereof. 
Except as expressly stated in this letter agreement, the Agreement
remains unchanged and in full force and effect in accordance with its terms.


 


*** Confidential Treatment Requested


 

















 


***Text Omitted and Filed Separately with the
Securities and Exchange


Commission. 
Confidential Treatment Requested Under


17 C.F.R.
Sections 200.80(b)(4) and 240.24b-2


 


Kindly
confirm your agreement to the above provisions by counter-signing this letter
below. Thank you for your prompt assistance with this matter.


 


Yours
sincerely,


 


Amylin Pharmaceuticals, Inc.


 


 


	
  /s/ David Banks

  	
   

  
	
  David Banks, VP Manufacturing

  	
   

  



 


 


ACKNOWLEDGED
AND AGREED:


 


 


Baxter Pharmaceutical Solutions LLC


 


 


	
  By:

  	
  /s/ Birk V. Eyre

  	
   

  
	
   

  	
   

  	
   

  
	
  Name:

  	
  Birk V. Eyre

  	
   

  
	
   

  	
   

  	
   

  
	
  Title:

  	
  General Manager
#### H. ABDALLAH v. CHARLES F. DUNN and CLARK MILLER.

(Filed 20 October, 1926.)

Appeal by defendant, Charles F. Dunn, from *Bond, J.,*at June Term, 1926, of LeNOIe. No error.

Two actions, one entitled “Clark Miller v. Charles F. Dunn,” and tbe other, “H. Abdallah v. Charles F. Dunn and Clark Miller,” pending in tbe Superior Court of Lenoir County, were consolidated for trial at June Term, 1924. Tbe relief demanded in both actions required an accounting between defendants Dunn and Miller. Dunn is tbe bolder, by endorsement of tbe payee, of a note secured by mortgage on land executed by Miller. Since Dunn became tbe owner of tbe note Miller has conveyed tbe land described in tbe mortgage to plaintiff, Abdallah, who, as part of tbe consideration for tbe conveyance, assumed payment of tbe note. There was a controversy between Miller and Dunn as to tbe amount due upon tbe note. From judgment in accordance with tbe verdict, and admissions in tbe record, defendant Dunn appealed to tbe Supreme Court.

*Sutton & Green for plaintiff..*

*Charles F. Dunn in propria sua.*

Per Curiam.

Upon an appeal by defendant Dunn to tbis Court, from judgment rendered at June Term, 1924, of Superior Court of Lenoir County, appellant’s assignments of error were sustained and a new trial ordered. *Miller v. Dunn,*188 N. C., 397. Issues necessary to a judgment finally determining tbe rights of tbe parties, involving tbe amount paid by Dunn to Copeland Bros., by whom tbe note was transferred to Dunn, and tbe application of payments, aggregating $100, made by Miller to Dunn, after tbe transfer of tbe note, were not submitted to tbe jury on tbe former trial. Upon tbe new trial tbe facts involved in tbe issues suggested have been found by tbe jury, upon competent evidence, and under instructions free from error. Appellant’s exceptions to tbe admission of evidence, to issues submitted, and to tbe judgment, cannot be sustained. Tbe judgment is affirmed. There is

No error.
##### 



Exhibit 10.50 [LETTERHEAD OF STI] July __, 2004 VIA FEDERAL EXPRESS
    
    PRIVILEGED AND CONFIDENTIAL«NAME»«ADDRESS»«CITYSTATEZIP»Dear «SAL»:
 This letter is to inform you that, subject to your agreement to the undertakings described
below, Superconductor Technologies Inc. (STI) intends, to the maximum extent permitted by the
Bylaws of STI (as restricted by applicable law), to advance your reasonable defense expenses
(including attorneys fees) incurred in connection with the following litigations (including any
related litigations which are subsequently filed) brought in the United States District Court for
the Central District of California (the Actions): Backhaus v. Superconductor Technologies Inc.., et al., CV 04-2680Goldfine v. Superconductor Technologies Inc.., et al., CV 04-2848Alvarez v. Superconductor Technologies Inc.., et al., CV 04-2927 This letter is also intended to confirm that you in good faith believe that you meet the
standard of conduct necessary for indemnification under Section 145 of the Delaware General
Corporation Law  that to the extent of your involvement in any matters that are the subject of any
of the Actions, you acted in good faith and in a manner you reasonably believed to be in or not
opposed to the best interests of STI. Section 145(e) and STIs Bylaws require that, should it
ultimately be determined that you are not entitled to be indemnified by STI as authorized by those
provisions, any advance payments made by STI on your behalf in connection with any of the Actions
as to which such a determination is made must be repaid by you to STI. Accordingly, you undertake to repay all amounts paid or reimbursed by STI on your behalf in
connection with the Actions if it shall ultimately be determined that, with respect to the subject
matter of the Actions, you are not entitled to be indemnified. You further agree that, by
advancing defense expenses on your behalf, STI does not waive or limit any right to recoupment of
such expenses from any insurance policies which may be applicable. STI acknowledges that you are
not waiving any rights you may have to indemnification under applicable corporate, employment or
other laws. Please acknowledge your agreement with the foregoing by signing and returning the enclosed
copy of this letter.




---



##### 



Very truly yours,SUPERCONDUCTOR TECHNOLOGIES, INC..,a Delaware corporationBy:Acknowledged and agreed:Date:[NAME]
 - 2 -
EXECUTIVE OFFICE OF THE PRESIDENT

OFFICE OF THE UNITED STATES TRADE REPRESENTATIVE

WASHINGTON, D.C. 20508

May 7, 2019

RE: Product Exclusion Request Number USTR-2018-0025-5451

Bosch Automotive Service Solutions Inc:

The purpose of this letter is to inform you that the product exclusion request referenced 

above has been denied. As you are aware, USTR published a Federal Register notice (83 FR 

28710) on June 20, 2018, that announced the Trade Representative’s determination to impose an 

additional duty of 25 percent on certain products from China. On July 11, 2018, the Trade 

Representative published a Federal Register notice (83 FR 32181) which announced that a 

process had been established under which interested persons could request that products falling 

within a covered HTSUS subheading be excluded from the additional duties announced on June 

20.

Your request was reviewed in accordance with the factors and procedures set forth in 

Section B(1) of the July 11 notice. Based on that review, and after careful consideration, your 

request was denied because the request failed to show that the imposition of additional duties on 

the particular product would cause severe economic harm to you or other U.S. interests.

Because USTR will grant exclusion requests on a product specific basis, you may still 

benefit from a product exclusion if a similar product is granted an exclusion. Products for which 

an exclusion has been granted will be periodically announced on the USTR website. Product 

exclusions will become legally effective once published in the Federal Register. 

Sincerely,

Joseph Barloon

General Counsel
EXHIBIT 32.1


                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


      In connection  with the Annual  Report of American Bio Medica  Corporation
(the  "Company") on Form 10-KSB for the period ending December 31, 2003 as filed
with the Securities and Exchange  Commission on May 10, 2004 (the "Report"),  I,
Edmund Jaskiewicz,  President of the Company, certify, pursuant to 18 U.S.C. ss.
1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that:

          (1)  The Report fully complies with the  requirements of section 13(a)
               or 15(d) of the Securities Exchange Act of 1934; and

          (2)  The information  contained in the Report fairly presents,  in all
               material  respects,   the  financial  condition  and  results  of
               operations of the Company.



                                              /s/ Edmund Jaskiewicz
                                              ---------------------------------
                                                  Edmund Jaskiewicz
                                                  President
                                                  (Principal Executive Officer)

                                                  May 10, 2004
Unassociated Document



Exhibit 10.11


LOAN AGREEMENT







THIS LOAN AGREEMENT, is made this tenth day of January, 2011, by and among American Tony Pharmaceutical Inc (hereinafter knows as “BORROWER”) and Mr. Mingli Yao(hereinafter knows as “LENDER”). BORROWER and LENDER shall collectively be known herein as “the Parties”. In determining the rights and duties of the Parties under this Loan Agreement, the entire document must be read as a whole.




 


In order to define the rights and obligations of the Borrowers and the Lender under relevant loan arrangements, the Parties hereby agree as follows:




 


Article 1 Amount and Interest Rate of Loan


 


1.1 Subject to the terms and conditions herein, the Lender agrees to provide the Borrowers with a line of credit up to RMB 4,000,000.


 


1.2 The interest rate of the Loan hereunder is 7% per year.


 


Article 2 Use and Term of Loan


 




	
2.1 

	
The term of the Loan hereunder shall be two(2) years, counted from the day when the Loan is provided and can be renewed every two years.









 




	
2.2 

	
The loan should be used for the company and its future development. Board of directors must approve it in order to use the loan.









 


Article 3 Defaulting Liabilities


 


3.1 The Borrowers undertake to hold the Lender harmless and indemnify the Lender against any actions, charges, claims, costs, damages, demands, expenses, liabilities, losses and proceedings which the Lender may suffer or be subject to as a result of any default by the Borrowers of its obligations hereunder.


 


3.2 Notwithstanding any other provisions herein, the validity of this Article shall survive the suspension or termination of this Agreement.


 







This agreement is made out in three originals, one for each party and one for American Tony Pharmaceutical Inc. All of them have the same force and effect.


 







 




  





  











  











 (Signature page)


 


IN WITNESS WHEREOF, the Parties have caused this Loan Agreement to be executed as of the date and in the place first set forth above.


 


By:


 


Name: Mingli Yao







 


American Tony Pharmaceutical Inc


 


By:


 


Name: Mingli Yao


 


Title: President
Exhibit 31.2

CERTIFICATION OF CFO PURSUANT TO RULE 13A-14(A) AND RULE 15D-14(A)

CERTIFICATIONS

I, Chris
D. Newman, certify that:

1. I have reviewed this Amendment No. 1 to the Annual Report on Form 10-K of Orchard Supply
Hardware Stores Corporation; and

2. Based on my knowledge, this report does not contain any untrue statement of a material
fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.



|                                                               
|---------------------------------------------------------------
|/s/ CHRIS D. NEWMAN                                            
|Chris D. Newman                                                
|Executive Vice President, Chief Financial Officer and Treasurer
|(Principal Financial Officer)                                  

Date: June 3, 2013
Exhibit 21

                     List of Subsidiaries of the Registrant
                     --------------------------------------

      The table below lists the Registrant subsidiaries. Unless otherwise
indicated, the Registrant, or one of its subsidiaries, own 100% of the
outstanding capital stock of the subsidiary.

      Name of Subsidiary                          Country of Incorporation
      ------------------                          ------------------------
      Senstar-Stellar Corporation                 Canada

      Perimeter Products Inc.                     United States

      Senstar-Stellar Inc.                        United States

      Senstar GmbH                                Germany

      Kobb Inc.                                   United States

      Magal B.V.                                  The Netherlands

      Senstar-Stellar Latin America S.A. de C.V.  Mexico

      Senstar-Stellar Limited                     United Kingdom

      Smart Interactive Systems, Inc.             United States

      E.S.E. Ltd.                                 Israel

      Magal Security Sisteme S.R.L                Romania (incorporated in April
                                                  2003)
[Federal Register Volume 60, Number 63 (Monday, April 3, 1995)]
[Notices]
[Pages 16884-16885]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-8051]



=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE

Information Collections Under Review
    The Office of Management and Budget (OMB) has been sent the 
following collection(s) of information proposals for review under the 
provisions of the Paperwork Reduction Act (44 USC Chapter 35) and the 
Paperwork Reduction Reauthorization Act since the last list was 
published. Entries are
[[Page 16885]] grouped into submission categories, with each entry 
containing the following information:

(1) The title of the form/collection;
(2) The agency form number, if any, and the applicable component of the 
Department sponsoring the collection
(3) Who will be asked or required to respond, as well as a brief 
abstract;
(4) An estimate of the total number of respondents and the amount of 
time estimated for an average respondent to respond;
(5) An estimate of the total public burden (in hours) associated with 
the collection; and,
(6) An indication as to whether Section 3504(h) of Public Law 96-511 
applies.

    Comments and/or suggestions regarding the item(s) contained in this 
notice, especially regarding the estimated public burden and associated 
response time, should be directed to the OMB reviewer, Mr. Jeff Hill on 
(202) 395-7304 AND to the Department of Justice's Clearance Officer, 
Mr. Robert B. Briggs, on (202) 514-4319. If you anticipate commenting 
on a form/collection, but find that time to prepare such comments will 
prevent you from prompt submission, you should notify the OMB reviewer 
AND the Department of Justice Clearance Officer of your intent as soon 
as possible. Written comments regarding the burden estimate or any 
other aspect of the collection may be submitted to Office of 
Information and Regulatory Affairs, Office of Management and Budget, 
Washington, DC 20503, AND to Mr. Robert B. Briggs, Department of 
Justice Clearance Officer, Systems Policy Staff/Information Resources 
Management/Justice Management Division Suite 850, WCTR, Washington, DC 
20530.
    Extension of a currently approved collection.
(1) Supplementary Homicide Report.
(2) I-704. Federal Bureau of Investigation, United States Department of 
Justice.
(3) Primary=State, Local, or Tribal Government. Others=None. This 
document is needed to collect Age, Sex, Race, ethnic origin and 
relationship of murder victims; the weapon and motive. Summary 
statistics are published in the annual report ``Crime in the United 
States.''
(4) 23,616 annual respondents at 10 minutes per response.
(5) 3,936 annual burden hours.
(6) Not applicable under Section 3504(h) of Public Law 96-511.

    Public comment on this item is encouraged.

    Dated: March 28, 1995.
Robert B. Briggs,
Department Clearance Officer, United States Department of Justice.
[FR Doc. 95-8051 Filed 3-31-95; 8:45 am]
BILLING CODE 4410-02-M
<PAGE>
 
                                  EXHIBIT 21

                        SUBSIDIARIES OF THE REGISTRANT
<PAGE>
 
                        SUBSIDIARIES OF THE REGISTRANT

                                   
                                                                    STATE OF
                                                     PERCENTAGE   INCORPORATION
                                                         OF            OR
     PARENT                    SUBSIDIARY             OWNERSHIP   ORGANIZATION 
     ------                    ----------            ----------   ------------

FORT BEND HOLDING CORP.    FORT BEND FEDERAL SAVINGS     100%       FEDERAL
                           AND LOAN ASSOCIATION OF
                           ROSENBERG

FORT BEND FEDERAL SAVINGS  FAIRVIEW, INC.                100%       TEXAS
AND LOAN ASSOCIATION OF 
ROSENBERG

FORT BEND FEDERAL          MITCHELL MORTGAGE              51%       TEXAS
SAVINGS AND LOAN           CORPORATION, L.L.C.
ASSOCIATION OF ROSENBERG
Exhibit 32.1

CERTIFICATION

Pursuant to the requirement set forth
in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the Exchange Act) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. § 1350, as adopted), Robert P. Akins, Chief
Executive Officer of Cymer, Inc., a Nevada corporation (the Registrant), hereby certifies that, to the best of his knowledge:



| | 1. | The Registrants annual report on Form 10-K for the period ended December 31, 2009, to which this certification is attached as Exhibit 32.1 (the
Report), fully complies with the requirements of Section 13(a) of the Exchange Act; and
| | -- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | 2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.
| | -- | -------------------------------------------------------------------------------------------------------------------------------------------------------

In Witness Whereof, the undersigned has set his hand hereto as of the 26th day of February, 2010.



|                       
|-----------------------
|/s/    ROBERT P.
AKINS 
|Robert P. Akins,       
|Chief Executive Officer

This certification accompanies the annual report on Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any
filing of Cymer, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the annual report on Form 10-K to which it relates), irrespective of any
general incorporation language contained in such filing.
EXHIBIT 99.4

 

**CERTIFICATION**

 

**Pursuant to 18 U.S.C. Section1350, as Enacted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

 

In connection with the annual reportof Enbridge Inc. (the “Corporation”) on Form 40-F for the fiscal year endingDecember 31, 2009, as filed with the Securities and Exchange Commission on thedate hereof (the “Report”), I, J. Richard Bird, Executive Vice President, ChiefFinancial Officer & Corporate Development of the Corporation, certify,pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of theSarbanes-Oxley Act of 2002, that:

 

1.            The Reportfully complies with the requirements of section 13(a) or 15(d) of theSecurities Exchange Act of 1934; and

2.            Theinformation contained in the Report fairly presents, in all material respects,the financial condition and results of operations of the Corporation.

 

Dated at Calgary, Alberta, this 18th day of February, 2010.

 

 
| “signed”                                                             |   |
|--------------------------------------------------------------------------------|--------|
| J. Richard  Bird                                                               |
| Executive Vice President, Chief Financial Officer  & Corporate Development |

 

----